Thermo Fisher Scientific reported its financial results for the third quarter ended September 28, 2024, with revenue of $10.60 billion, which was flat compared to $10.57 billion in the prior-year quarter and marginally missed consensus estimates of $10.64 billion. Despite this, the company's adjusted diluted EPS for the quarter was $5.28, surpassing analyst expectations, though it was lower than $5.69 in the third quarter of 2023.
GAAP diluted EPS for Q3 2024 was $4.25, down from $4.42 in the same period last year, while GAAP operating income was $1.84 billion, compared with $1.86 billion in the year-ago quarter. Adjusted operating income for the quarter was $2.36 billion, a decrease from $2.56 billion in the prior year, resulting in an adjusted operating margin of 22.3%, down from 24.2%.
For the full year 2024, Thermo Fisher raised its adjusted EPS guidance to a new range of $21.35 to $22.07, up from its previous guidance of $21.29 to $22.07. The company maintained its revenue guidance in the range of $42.4 billion to $43.3 billion, indicating a stable outlook despite the mixed quarterly performance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.